TY - JOUR
T1 - Multifunctional nanostructures
T2 - Intelligent design to overcome biological barriers
AU - Azizi, Mehdi
AU - Jahanban-Esfahlan, Rana
AU - Samadian, Hadi
AU - Hamidi, Masoud
AU - Seidi, Khaled
AU - Dolatshahi-Pirouz, Alireza
AU - Yazdi, Amirhossein Ahmadieh
AU - Shavandi, Amin
AU - Laurent, Sophie
AU - Hagh, Mahsa Be Omide
AU - Kasaiyan, Nahid
AU - Santos, Hélder A.
AU - Shahbazi, Mohammad-Ali
PY - 2023/6
Y1 - 2023/6
N2 - Over the past three decades, nanoscience has offered a unique solution for reducing the systemic toxicity of chemotherapy drugs and for increasing drug therapeutic efficiency. However, the poor accumulation and pharmacokinetics of nanoparticles are some of the key reasons for their slow translation into the clinic. The is intimately linked to the non-biological nature of nanoparticles and the aberrant features of solid cancer, which together significantly compromise nanoparticle delivery. New findings on the unique properties of tumors and their interactions with nanoparticles and the human body suggest that, contrary to what was long-believed, tumor features may be more mirage than miracle, as the enhanced permeability and retention based efficacy is estimated to be as low as 1%. In this review, we highlight the current barriers and available solutions to pave the way for approved nanoformulations. Furthermore, we aim to discuss the main solutions to solve inefficient drug delivery with the use of nanobioengineering of nanocarriers and the tumor environment. Finally, we will discuss the suggested strategies to overcome two or more biological barriers with one nanocarrier. The variety of design formats, applications and implications of each of these methods will also be evaluated.
AB - Over the past three decades, nanoscience has offered a unique solution for reducing the systemic toxicity of chemotherapy drugs and for increasing drug therapeutic efficiency. However, the poor accumulation and pharmacokinetics of nanoparticles are some of the key reasons for their slow translation into the clinic. The is intimately linked to the non-biological nature of nanoparticles and the aberrant features of solid cancer, which together significantly compromise nanoparticle delivery. New findings on the unique properties of tumors and their interactions with nanoparticles and the human body suggest that, contrary to what was long-believed, tumor features may be more mirage than miracle, as the enhanced permeability and retention based efficacy is estimated to be as low as 1%. In this review, we highlight the current barriers and available solutions to pave the way for approved nanoformulations. Furthermore, we aim to discuss the main solutions to solve inefficient drug delivery with the use of nanobioengineering of nanocarriers and the tumor environment. Finally, we will discuss the suggested strategies to overcome two or more biological barriers with one nanocarrier. The variety of design formats, applications and implications of each of these methods will also be evaluated.
KW - Nanoparticles engineering
KW - Cancer
KW - Nanotechnology
KW - Targeted drug delivery
KW - Biological barriers
KW - Biotechnology
U2 - 10.1016/j.mtbio.2023.100672
DO - 10.1016/j.mtbio.2023.100672
M3 - Article
SN - 2590-0064
VL - 20
JO - Materials Today Bio
JF - Materials Today Bio
M1 - 100672
ER -